A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.
Buter
J
J
Department of Medical Oncology, University Hospital, Groningen, The Netherlands.
Sleijfer
D T
DT
van der Graaf
W T
WT
de Vries
E G
EG
Willemse
P H
PH
Mulder
N H
NH
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012646:Self Administration; D016019:Survival Analysis
D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin